YB-1-basierte Virotherapie: Ein neues Therapiekonzept beim Urothelkarzinom der Harnblase

Translated title of the contribution: YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Therapeutic intervention using oncolytic viruses is called virotherapy. This type of virus is defined by the ability to replicate in tumor cells only and to destroy these cells upon replication. In addition, this virus type is able to induce a tumor-directed immune response. Early clinical trials have confirmed the safety profile of oncolytic viruses. Currently, different groups are working on the development of oncolytic viruses with a focus on treatment of nonmuscle invasive bladder cancer (NMIBC). A preliminary active recruiting clinical phase II/III trial ongoing in patients with a NMIBC was recently implemented in the United States. Our research group developed an oncolytic adenovirus that will soon enter a clinical phase I trial in patients diagnosed with glioma. This virus is being further modified for the treatment of NMIBC. In this review article, recent developments in the design and use of virotherapy in bladder cancer are summarized.

Translated title of the contributionYB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?
Original languageGerman
Pages (from-to)356-363
Number of pages8
JournalUrologe - Ausgabe A
Volume55
Issue number3
DOIs
StatePublished - 1 Mar 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?'. Together they form a unique fingerprint.

Cite this